Conversations continue for access to new treatments
We appreciate that it has been a couple of months since the Pharmaceutical Benefits Advisory Committee (PBAC) recommended that 4 new treatments for AChR+ generalised MG patients be listed on the Pharmaceutical Benefits Scheme (PBS)… In this time, the MAA has continued conversations with clinicians, government, and industry stakeholders to make sure we understand the progress of these recommendations, and we continue to advocate for improved access to treatments.
The Public Summary Documents (PSDs) for the PBC March 2025 meeting were published online on 4th July 2025. HOWEVER, PSDs for the 4 treatments for gMG patients are still pending publication.
This means that more discussion is required and we appreciate the work being done by the department and pharmaceutical companies. While Australia has a rigorous process for approving medications and treatments on the PBS, the key point for us here is that a commitment remains from all stakeholders and things are still moving.
The MAA remains committed to ensuring that MG patients in Australia have equitable and timely access to the best available treatment that most benefits them. We remind stakeholders that timing is important to us and we do not wish to delay access unnecessarily.
We also reiterate the impact of our submissions to PBAC earlier this year, which established the high unmet clinical needs of our patient community. The MAA maintains that this demonstrates a clear need for access to treatment options to improve the quality of life for all MG patients.
We understand that some patients are accessing these new treatments via Early Access Programs (EAPs). The MAA and State Associations would still be glad to receive feedback from people who are receiving these treatments via EAPs so please reach out by emailing info@mgaq.org.au or info@myasthenia.org.au, or calling 1800 802 568.
We will keep you updated on the progress of these new treatments being available on the PBS, including when the PSDs are published. Please check that you’re subscribed to updates via the MAA website.